Compare AbCellera Biologics Inc (ABCL) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? AbCellera Biologics Inc trades at $11.8 (market cap $3.82B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $28.04 (market cap $2.01B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold AbCellera Biologics Inc for 41 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 31 Days on average.
| ABCL | TMF | |
|---|---|---|
Market Cap | $3.82B | $2.01B |
Volume | 4,098,108 | 6,566,364 |
Sector | Health | Fixed Income |
52-Week High | $14.82 | $44.14 |
52-Week Low | $2.78 | $25.19 |
Typical Hold Time | 41 Days | 31 Days |
Enterprise Value | $3.42B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $11.80, down 6.94% today but has surged 121% over three months following positive Phase 2 results for ABCL635. The stock shows bullish technical signals with strong analyst support (91.67% buy ratings) and a $15.40 consensus price target. Despite negative margins and cash burn, recent clinical success and a $200 million oversubscribed offering provide optimism for future growth.
The outlook balances promising drug development against fundamental challenges. ABCL635's success could drive significant upside, but investors face risks from ongoing losses, high cash burn, and reliance on pipeline execution. The stock offers high-risk, high-reward potential for biotech investors comfortable with clinical-stage volatility.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) is trading at $28.04, up 4.28% with strong bullish technical signals from moving averages and oscillators. The ETF saw increased trading volume of 5.2 million shares, indicating heightened investor interest in long-term Treasury exposure. Technical indicators show RSI at overbought levels while ADX signals strong trend momentum.
The outlook remains positive for Treasury-focused ETFs as investors seek safe-haven assets, though overbought RSI conditions suggest potential near-term consolidation. Key risks include interest rate volatility and macroeconomic policy shifts that could impact long-term bond performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
